Servier Drug Patent Portfolio

Servier owns 2 orange book drugs protected by 15 US patents Given below is the list of Servier's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10980788 Therapy for treating malignancies 07 Jun, 2039
Active
US11345677 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same 16 Jan, 2039
Active
US10653710 Combination therapy for treating malignancies 18 Oct, 2036
Active
US11844758 Therapeutically active compounds and their methods of use 04 Dec, 2035
Active
US10449184 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
Active
US10799490 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
Active
US9968595 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
Active
US10172864 Therapeutically active compounds and their methods of use 11 Jul, 2034
Active
US12433895 Therapeutically Active Compounds And Their Methods Of Use 11 Jul, 2034
Active
US9579324 Therapeutically active compounds and their methods of use 11 Jul, 2034
Active
US9474779 Therapeutically active compositions and their methods of use 19 Aug, 2033
Active
US10717764 Therapeutically active compounds and their methods of use 18 Jan, 2033
Active
US11667673 Therapeutically active compounds and their methods of use 18 Jan, 2033
Active
US9850277 Therapeutically active compositions and their methods of use 18 Jan, 2033
Active
US10610125 Methods and compositions for cell-proliferation-related disorders 21 Jun, 2030
Active


Given below is the list of recent legal activities going on the following drug patents of Servier.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 12 Nov, 2025 US11345677
Patent eCofC Notification 11 Nov, 2025 US12433895
Email Notification 11 Nov, 2025 US12433895
Recordation of Patent eCertificate of Correction 11 Nov, 2025 US12433895
Mail Patent eCofC Notification 11 Nov, 2025 US12433895
Payment of Maintenance Fee, 8th Year, Large Entity 29 Oct, 2025 US9968595
Post Issue Communication - Certificate of Correction 20 Oct, 2025 US12433895
Recordation of Patent Grant Mailed 14 Oct, 2025 US12433895
Patent Issue Date Used in PTA Calculation 07 Oct, 2025 US12433895
Email Notification 07 Oct, 2025 US12433895
Mail Patent eGrant Notification 07 Oct, 2025 US12433895
Recordation of Patent eGrant 07 Oct, 2025 US12433895
Patent eGrant Notification 07 Oct, 2025 US12433895
Email Notification 25 Sep, 2025 US12433895
Issue Notification Mailed 24 Sep, 2025 US12433895


Servier's Drug Patent Litigations

Servier's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 15, 2022, against patent number US10610125. The petitioner Rigel Pharmaceuticals, Inc., challenged the validity of this patent, with Servier Pharmaceuticals LLC et al. as the respondent. Click below to track the latest information on how companies are challenging Servier's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10610125 August, 2022 Terminated-Settled
(06 Jan, 2023)
Servier Pharmaceuticals LLC et al. Rigel Pharmaceuticals, Inc.


Servier's Family Patents

Servier drugs have patent protection in a total of 39 countries. It's US patent count contributes only to 22.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents





Clinical Trials

Recent Clinical Trials by Servier:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies Institut de Recherches Internationales Servier NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation Institut de Recherches Internationales Servier NA RECRUITING
(Sep 1, 2026)
PHASE3
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation Institut de Recherches Internationales Servier (I.R.I.S.) NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment Servier Bio-Innovation LLC NA RECRUITING
(Aug 1, 2026)
PHASE1
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma Servier Affaires Médicales NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma Institut de Recherches Internationales Servier NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies Servier NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation Institut de Recherches Internationales Servier NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation Servier NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants Institut de Recherches Internationales Servier (I.R.I.S.) NA RECRUITING
(Jun 1, 2026)
PHASE1
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation Institut de Recherches Internationales Servier NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia Institut de Recherches Internationales Servier NA COMPLETED
(May 1, 2026)
PHASE1, PHASE2
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. Servier Affaires Médicales NA RECRUITING
(May 1, 2026)
PHASE3
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas Institut de Recherches Internationales Servier NA COMPLETED
(May 1, 2026)
PHASE2
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation Institut de Recherches Internationales Servier NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2
A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants Institut de Recherches Internationales Servier (I.R.I.S.) NA COMPLETED
(May 1, 2026)
PHASE1
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma Servier Bio-Innovation LLC NA TERMINATED
(Mar 1, 2026)
PHASE1, PHASE2
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML Servier Bio-Innovation LLC NA TERMINATED
(Mar 1, 2026)
PHASE1, PHASE2


Servier Drug List

Given below is the complete list of Servier's drugs and the patents protecting them.


1. Tibsovo

Tibsovo is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10980788 Therapy for treating malignancies 07 Jun, 2039
(12 years from now)
Active
US10653710 Combination therapy for treating malignancies 18 Oct, 2036
(10 years from now)
Active
US10449184 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
(8 years from now)
Active
US10799490 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
(8 years from now)
Active
US9968595 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
(8 years from now)
Active
US9474779 Therapeutically active compositions and their methods of use 19 Aug, 2033
(6 years from now)
Active
US10717764 Therapeutically active compounds and their methods of use 18 Jan, 2033
(6 years from now)
Active
US11667673 Therapeutically active compounds and their methods of use 18 Jan, 2033
(6 years from now)
Active
US9850277 Therapeutically active compositions and their methods of use 18 Jan, 2033
(6 years from now)
Active
US10610125 Methods and compositions for cell-proliferation-related disorders 21 Jun, 2030
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tibsovo's drug page


2. Voranigo

Voranigo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11345677 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same 16 Jan, 2039
(12 years from now)
Active
US11844758 Therapeutically active compounds and their methods of use 04 Dec, 2035
(9 years from now)
Active
US10172864 Therapeutically active compounds and their methods of use 11 Jul, 2034
(7 years from now)
Active
US12433895 Therapeutically Active Compounds And Their Methods Of Use 11 Jul, 2034
(7 years from now)
Active
US9579324 Therapeutically active compounds and their methods of use 11 Jul, 2034
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Voranigo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Servier News

Incorporating Artificial Intelligence and Machine Learning into the Process of Drug Discovery and Development

14 Jan, 2026

FDA Approves First-In-Class Treatment for Two Types after Servier's Successful Acquisition

07 Aug, 2024

See More